In addition, TIE1 has been shown to promote cisplatin resistance in ovarian cancer by upregulating xeroderma pigmentosum complementation group C (XPC)-mediated nucleotide excision repair (NER), decreasing cell sensitivity to cisplatin 31. The gene discussed is TIE1; the disease is ovarian carcinoma.